The Prognostic Value of Dynamic Changes in Peripheral Blood Lymphocyte Subsets During Chemotherapy for Breast Cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500105256

Enrollment

Unknown

Registered

2025-07-01

Start date

2025-07-07

Completion date

Unknown

Last updated

2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Case series:NA

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: (1) Pathologically confirmed primary malignant tumor of the breast; (2) Undergo radical surgery for breast cancer according to the treatment plan; (3) Receive neoadjuvant chemotherapy before surgery or adjuvant chemotherapy after surgery.

Exclusion criteria

Exclusion criteria: ?(1) Presence of distant metastasis at initial breast cancer diagnosis;? ??(2) do not undergo radical surgery for breast cancer;? ??(3) No clinical indication for neoadjuvant or adjuvant chemotherapy;? ??(4) Refuse peripheral blood lymphocyte subset testing or failed to complete follow-up as scheduled;? ??(5) Occurrence of severe infectious diseases during chemotherapy.?

Design outcomes

Primary

Measure	Time frame
Peripheral Blood Lymphocyte subset CD4+/CD8+;	—

Countries

China

Contacts

Public ContactHongliang Chen, Kejin Wu

Obstetrics and Gynecology Hospital of Fudan University

17131250024@fudan.edu.cn+86 136 7185 2284

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026